Displaying 201 - 220 of 305
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
The Commission charged that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future.
There is a related federal proceeding and two related administrative proceedings:
FTC Chairman, Members of Congress Call for Legislation to End Sweetheart Pay-for-Delay Deals That Keep Generic Drugs Off the Market
FTC Order Ensures Future Competition for Parkinsons and Chemotherapy Drugs That Watsons Acquisition of Arrow Would Have Eliminated
FTC Order Restores Competition Lost Through Schering-Plough's Acquisition of Merck
Statement of FTC Chairman Jon Leibowitz Regarding the Senate Judiciary Committee's Passage of the Preserve Access to Affordable Generics Act (S. 369)
FTC Order Prevents Anticompetitive Effects from Pfizers Acquisition of Wyeth
Statement by FTC Chairman Jon Leibowitz on Adoption of the Pay for Delay Amendment to the Americas Affordable Health Choices Act of 2009 by the House Energy and Commerce Committee
FTC Issues Interim Report on "Authorized Generic" Drugs
FTC Chairman Leibowitz: Eliminating Pay-for-Delay Pharmaceutical Settlements Would Save Consumers $3.5 Billion Annually
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
FTC Testifies on "Competition Issues and Follow-on Biologic Drugs"
FTC Releases Report on Follow-on Biologic Drug Competition
Statement of the FTC's Bureau of Competition Regarding the Announcement that CSL Will Not Proceed with its Proposed Acquisition of Talecris Biotherapeutics
FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies
FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics
FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies
Bristol-Myers Squibb to Pay $2.1 Million Penalty for Failure to Disclose Agreement Involving Substantial Payments to Delay Entry of a Generic Version of the Drug Plavix
Teva Pharmaceutical Industries Ltd., a corporation, and Barr Pharmaceuticals, Inc., a corporation, In the Matter of
In December 2008, the Commission settled antitrust concerns raised by the proposed $8.9 billion acquisition of Barr Pharmaceuticals by Teva Pharmaceutical Industries. The proposed acquisition would have lessened competition in the markets for 17 commonly used generic medications including drugs used in the treatment of cancer, bacterial infections, diabetes, acid reflux, and depression as well as several varieties of oral contraceptives. According to the Commission’s complaint, the acquisition would have likely led to higher prices for consumers through the removal of one of only four competitors in each of these markets. The Commission’s consent agreement requires both Teva and Barr to sell assets in 29 U.S. markets to either Watson Pharmaceuticals or Qualitest Pharmaceuticals.
Commission Approves Final Consent Order in Matter of AllCare IPA; FTC Approves Final Consent Order in Matter of King Pharmaceuticals/Alpharma Inc.
Displaying 201 - 220 of 305